Polymorphism engineering of mefenamic acid for enhanced pharmacokinetic performance

Authors

  • Parteek Prasher Department of Chemistry, University of Petroleum & Energy Studies (UPES), Dehradun, 248007, India; E-mail: parteekchemistry@gmail.com and pprasher@ddn.upes.ac.in https://orcid.org/0000-0002-9412-9424
  • Mousmee Sharma Department of Chemistry, Uttaranchal University, Dehradun, 248007, India https://orcid.org/0000-0002-7728-5054

DOI:

https://doi.org/10.17179/excli2026-9258

Keywords:

Mefenamic acid, crystal structure, polymorphism, pharmacokinetics, formulation

Abstract

Mefenamic acid, a BCS Class II drug, continues to face the longstanding challenges related to its suboptimal solubility and variable absorption, which necessitates frequent dosing of the drug resulting in ulcerogenicity. Guided by its polymorphic forms, the co-crystallization of mefenamic acid offers a unique advantage over the other advanced formulation strategies, including hydrotropy, nanosizing, and complexation for improving the drug bioavailability. However, the contemporary research limited only to the proof-of-concept studies fails to provide a clinical evidence or translational insights, which necessitates the rational design of synthons and engineering of the solid-state landscape of the drug for developing the co-crystallization formulation of mefenamic acid. This commentary provides critical insights into the polymorphism-driven co-crystal design of mefenamic acid aimed at filling the critical gaps in scalability and clinical translation.

Downloads

Published

2026-03-17

How to Cite

Prasher, P., & Sharma, M. (2026). Polymorphism engineering of mefenamic acid for enhanced pharmacokinetic performance. EXCLI Journal, 25, 390–395. https://doi.org/10.17179/excli2026-9258

Issue

Vol. 25 (2026)

Section

Letters to the editor

Categories

License

Copyright (c) 2026 Parteek Prasher, Mousmee Sharma

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish in this journal agree to the following terms:

  • The authors keep the copyright and grant the journal the right of first publication under the terms of the Creative Commons Attribution license, CC BY 4.0. This licencse permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited.
  • The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
  • Because the advice and information in this journal are believed to be true and accurate at the time of publication, neither the authors, the editors, nor the publisher accept any legal responsibility for any errors or omissions presented in the publication. The publisher makes no guarantee, express or implied, with respect to the material contained herein.
  • The authors can enter into additional contracts for the non-exclusive distribution of the journal's published version by citing the initial publication in this journal (e.g. publishing in an institutional repository or in a book).

Most read articles by the same author(s)